Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Accounts Payables (2016 - 2020)

Monopar Therapeutics (MNPR) has disclosed Accounts Payables for 5 consecutive years, with $542068.0 as the latest value for Q3 2020.

  • Quarterly Accounts Payables rose 12.07% to $542068.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $542068.0 through Sep 2020, up 12.07% year-over-year, with the annual reading at $724165.0 for FY2019, 81.24% up from the prior year.
  • Accounts Payables hit $542068.0 in Q3 2020 for Monopar Therapeutics, up from $525748.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $724165.0 in Q4 2019 to a low of $64510.0 in Q4 2016.
  • Historically, Accounts Payables has averaged $420685.1 across 5 years, with a median of $443520.0 in 2020.
  • Biggest five-year swings in Accounts Payables: skyrocketed 383.44% in 2017 and later fell 23.53% in 2020.
  • Year by year, Accounts Payables stood at $64510.0 in 2016, then surged by 383.44% to $311867.0 in 2017, then rose by 28.12% to $399551.0 in 2018, then soared by 81.24% to $724165.0 in 2019, then fell by 25.15% to $542068.0 in 2020.
  • Business Quant data shows Accounts Payables for MNPR at $542068.0 in Q3 2020, $525748.0 in Q2 2020, and $443520.0 in Q1 2020.